Research ArticleOpen accessIn the author namesCELL DETACHMENT BY PROLYL-SPECIFIC ENDOPEPTIDASE FROM WOLFIPORIA COCOSNicole Mika, Katharina Cierpka, Michaela C. Lange et al.As requirements for Advanced Therapy Medicinal Product (ATMP) production differ from other production processes (e.g., therapeutic protein production), cell detachment is often a crucial step for the process success. In most cases, cell detachment is done enzymatically. Although many peptidases are established in cell culture in R&D, e.g., Trypsin as gold standard, many of them seem to be unsuitable in … …American Journal of Biochemistry and Biotechnology, Vol. 10, Issue 1 · 8 Feb 2014 · 8,157 accessesView PDFCite
Research ArticleOpen accessIn the author namesInfluence of Process Conditions on Measles Virus StabilityK. Weiss, D. Salzig, J. Gerstenberger et al.Recombinant measles viruses are currently tested in clinical trials as oncolytic agent to be applied in cancer therapy. Contrary to their use as vaccine where 103 infectious virus particles per dose are needed, for cancer therapy 109 virus particles should be provided per dose. This leads to other challenges for the production process when compared to vaccine production. This study … …American Journal of Biochemistry and Biotechnology, Vol. 9, Issue 3 · 21 Sep 2013 · 9,949 accessesView PDFCite
Research ArticleOpen accessIn the author namesKEY PARAMETERS OF MEASLES VIRUS PRODUCTION FOR ONCOLYTIC VIROTHERAPYK. Weiss, D. Salzig, M. D. Mühlebach et al.Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic therapy can be more than a million times higher compared to vaccination. This requires highly effective production processes which guarantee the measles virus quantities needed for its use … …American Journal of Biochemistry and Biotechnology, Vol. 8, Issue 2 · 22 Jun 2012 · 9,785 accessesView PDFCite